{"product_id":"23andme-five-forces-analysis","title":"23andMe Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003e23andMe faces intense rivalry from established labs and direct-to-consumer startups, rising regulatory scrutiny, moderate supplier leverage for genotyping tech, strong buyer power from price-sensitive consumers, and notable substitute threats from clinical testing and emerging at-home diagnostics.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore 23andMe’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Genotyping Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe depends on few suppliers for genotyping arrays and lab gear—most notably Illumina—giving suppliers strong leverage; Illumina held roughly 70% of the short-read sequencing market in 2024, so 23andMe faces limited supplier alternatives. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud Infrastructure and Data Storage Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManaging and analyzing petabytes of genomic data forces 23andMe to rely on cloud giants like Amazon Web Services and Google Cloud; in 2024 public cloud IaaS spending hit about $230B globally, and egress and specialized compute for genomics can push per-sample cloud costs into tens of dollars, so infrastructure is a material operating expense.\u003c\/p\u003e\n\u003cp\u003eMultiple providers exist, but moving petabytes of sensitive data is complex and costly—estimates show multi-month migrations and transfer bills of millions—creating vendor lock-in and giving providers moderate-to-high pricing power over 23andMe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Specialized Shipping Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe relies on global carriers to deliver ~6 million annual collection kits (2024 estimate) and return bio-samples to labs, creating dependence on logistics partners. The need for temperature control, chain-of-custody tracking, and regulatory compliance narrows viable vendors to a few specialized couriers, raising suppliers’ bargaining power. In 2023, industry disruptions (border delays, COVID-19 waves) caused sample transit times to spike 20–30%, directly harming customer experience and risking sample integrity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Pharmaceutical Research Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of research opportunities, notably GlaxoSmithKline (GSK) and similar pharma partners, hold leverage by funding multi-year drug‑discovery deals that supplied 23andMe with over $300m in collaboration revenue and equity through 2023–2025.\u003c\/p\u003e\n\u003cp\u003eThese partners set trial timelines, IP and milestone terms crucial for 23andMe’s biotech pivot; withdrawal or tougher renegotiation could cut projected research revenue growth and reduce long‑term royalty streams by tens of millions annually.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGSK deal scale: ~$300m+ through 2025\u003c\/li\u003e\n\u003cli\u003eMulti‑year terms: control IP\/milestones\u003c\/li\u003e\n\u003cli\u003ePartner exit risk: large hit to future research revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Consumables and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe DNA extraction and analysis workflow at 23andMe depends on continuous delivery of high-grade reagents and consumables, with 2024 procurement totaling about $45M for lab supplies, reflecting \u0026gt;60% of variable lab costs.\u003c\/p\u003e\n\u003cp\u003eThese inputs must meet strict CLIA and CAP quality standards to keep genotype accuracy and regulatory compliance, so switching suppliers risks validation delays of 4–8 weeks.\u003c\/p\u003e\n\u003cp\u003eOnly a handful of global chemical manufacturers supply these specialized items at scale, giving them leverage to raise prices and squeeze 23andMe’s lab margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 lab supplies spend ~$45M\u003c\/li\u003e\n\u003cli\u003eSuppliers few—low bargaining power for buyer\u003c\/li\u003e\n\u003cli\u003eSupplier price hikes can delay validation 4–8 weeks\u003c\/li\u003e\n\u003cli\u003eQuality standards: CLIA and CAP compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance and vendor lock‑in: Illumina, cloud costs, and high switching barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: Illumina ~70% short‑read market (2024), cloud IaaS ~$230B spend (2024) with per‑sample cloud costs in tens of dollars, lab supplies ~$45M (2024) \u0026gt;60% variable lab costs, ~6M kits shipped (2024), GSK collaboration ~$300M+ through 2025; switching costs, validation delays 4–8 weeks, and logistics complexity create vendor lock‑in.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina market share\u003c\/td\u003e\n\u003ctd\u003e~70% short‑read\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud IaaS spend\u003c\/td\u003e\n\u003ctd\u003e$230B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer‑sample cloud cost\u003c\/td\u003e\n\u003ctd\u003eTens of $\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab supplies spend\u003c\/td\u003e\n\u003ctd\u003e$45M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual kits shipped\u003c\/td\u003e\n\u003ctd\u003e~6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK deal\u003c\/td\u003e\n\u003ctd\u003e$300M+ through 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for 23andMe, this Porter's Five Forces overview uncovers key competitive drivers, buyer and supplier influence, threats from substitutes and new entrants, and strategic levers that affect its pricing power and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces for 23andMe—one-sheet clarity to assess competitive intensity and strategic levers instantly, ready to drop into decks or expand with your data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Individual Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual customers face minimal switching costs for a one-time 23andMe genetic test; DNA reports are portable and a typical kit cost fell to about $99–$129 in 2024, so users aren’t financially locked into one ecosystem.\u003c\/p\u003e\n\u003cp\u003eThat portability and low upfront spend means churn risk is real—23andMe reported 2024 consumer revenue of roughly $280M, so it must keep innovating and pricing competitively to protect market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in the DTC Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe DTC genetic-testing market is highly price-sensitive: 23andMe reported average kit revenues fell 12% in 2024 amid heavy discounting, and Google Trends shows purchase intent spikes during holiday sales and 20–30% off promos. Consumers delay purchases for bundles, capping willingness to pay and tying perceived value to promotions. This sensitivity limits 23andMe’s ability to raise list prices without volume declines; a 10% price hike could cut unit sales by an estimated 15–25% based on 2023–24 elasticity data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBargaining Leverage of Large Institutional Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge pharma and academic partners buying aggregated 23andMe genetic datasets exert strong bargaining power because a small number of buyers generate major B2B revenue; in 2024 23andMe reported 23% of revenue from Therapeutics and Research deals, with top partners like GSK and Pfizer able to demand custom data formats, HIPAA-level security and volume discounts often exceeding 10–20% on multi-year contracts worth tens to hundreds of millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Concern over Data Privacy and Ownership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpas public awareness of data privacy rises customers demand control over genetic and reported users requested deletion or research opt-out in directly shrinking its asset base potential revenue from partnerships.\u003e\n\u003cpto keep trust must honor opt-outs and delete requests which limits monetization research revenue was could fall if opt-out rates rise above current levels.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e12% user opt-out\/deletion requests in 2024\u003c\/li\u003e\u003cli\u003e$40M research revenue in 2024\u003c\/li\u003e\u003cli\u003eHigher opt-outs cut dataset value and partner deals\u003c\/li\u003e\n\u003c\/pto\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift Toward Subscription-Based Revenue Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e23andMe’s 23andMe+ subscription (launched 2021) boosts lifetime value by adding recurring revenue—subscriptions drove an estimated 10–15% of revenue by 2024—reducing one-time buyer leverage.\u003c\/p\u003e\n\u003cp\u003eStill, subscribers can cancel anytime, so buyer power persists: churn rates matter; industry-average digital health subscription churn ~4–6% monthly in 2023, so 23andMe must keep churn below that to sustain ARR.\u003c\/p\u003e\n\u003cp\u003eThe model forces continuous product updates: regular release of new health reports and research partnerships (e.g., 2022+ GWAS outputs) needed to justify $29\/yr pricing and prevent downgrades.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscriptions increased recurring revenue share to ~10–15% by 2024\u003c\/li\u003e\n\u003cli\u003eIndustry churn 4–6% monthly—key KPI for buyer power\u003c\/li\u003e\n\u003cli\u003e$29\/yr price point requires ongoing new reports and partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh buyer leverage: low switching costs, $99–$129 kits, opt-outs \u0026amp; partner power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers have high leverage: low switching costs, portable DNA, and kit prices around $99–$129 in 2024 keep price sensitivity and churn pressure high; 23andMe’s 2024 consumer revenue ~$280M and 12% user opt-outs amplify that power.\u003c\/p\u003e\n\u003cp\u003eLarge B2B partners hold strong bargaining power over data\/price (research revenue ~$40M in 2024); subscriptions (10–15% revenue) help but churn risk persists.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer revenue\u003c\/td\u003e\n\u003ctd\u003e$280M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch revenue\u003c\/td\u003e\n\u003ctd\u003e$40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUser opt-outs\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription share\u003c\/td\u003e\n\u003ctd\u003e10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKit price\u003c\/td\u003e\n\u003ctd\u003e$99–$129\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e23andMe Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact 23andMe Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders, no mockups.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is part of the full, professionally formatted file you’ll be able to download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: a ready-to-use, fully written analysis of competitive pressures facing 23andMe, available instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746697195897,"sku":"23andme-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/23andme-five-forces-analysis.png?v=1772191061","url":"https:\/\/matrixbcg.com\/products\/23andme-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}